MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Viatris Total Shareholders Equity 2011-2026 | VTRS
Annual Total Shareholders Equity Viatris
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 B | 18.6 B | 20.5 B | 21.1 B | 20.5 B | 23 B | - | 12.2 B | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23 B | 12.2 B | 18.6 B |
Quarterly Total Shareholders Equity Viatris
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 B | 15.2 B | 15.6 B | 15.7 B | 19.8 B | 19.5 B | 20 B | 20.9 B | 20.8 B | 20.9 B | 21.1 B | 19.2 B | 19.8 B | 20.4 B | 20.5 B | 21.1 B | 21.2 B | 21.4 B | 23 B | -201 M | -1 M | - | - | - | - | - | 12.2 B | - | - | - | 13.3 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23 B | -201 M | 17.2 B |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
7.04 M | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
766 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
9.13 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
24.9 M | $ 6.39 | 8.86 % | $ 94.9 M | USA |
 |
Cronos Group
CRON
|
1.09 B | $ 2.74 | -0.18 % | $ 1.05 B | Canada |
 |
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
52.4 M | $ 33.13 | 0.38 % | $ 1.22 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
-554 M | $ 5.56 | 1.65 % | $ 2.06 B | Canada |
 |
Organogenesis Holdings
ORGO
|
300 M | $ 2.62 | -1.69 % | $ 332 M | USA |
 |
Pacira BioSciences
PCRX
|
778 M | $ 23.26 | -0.41 % | $ 1.08 B | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.08 | 3.84 % | $ 116 M | Canada |
 |
Solid Biosciences
SLDB
|
180 M | $ 6.91 | 4.31 % | $ 605 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.51 | 1.45 % | $ 192 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 1.12 | 1.36 % | $ 1.39 M | USA |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
3.32 B | $ 5.46 | 3.22 % | $ 3.37 B | Canada |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.14 | 1.34 % | $ 109 M | Canada |
 |
Evolus
EOLS
|
-23.1 M | $ 6.07 | -0.33 % | $ 391 M | USA |
 |
Sundial Growers
SNDL
|
270 M | $ 1.46 | 0.69 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
523 M | $ 8.93 | 5.68 % | $ 478 M | USA |
 |
Veru
VERU
|
18.3 M | $ 2.39 | 1.86 % | $ 35 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
94 M | $ 23.45 | 0.04 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
7.23 M | $ 0.75 | -1.83 % | $ 3.02 M | USA |
 |
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.95 | -1.35 % | $ 274 M | USA |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.73 | -0.29 % | $ 36.5 M | USA |
 |
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | - | - | $ 29.1 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 0.79 | 3.21 % | $ 3.39 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.02 | -4.71 % | $ 23.4 M | USA |